Abstract
The effects of isosorbide dinitrate (ISDN) and its 2- and 5-mononitrate metabolites (2-ISMN and 5-ISMN) against platelet aggregation and thromboxane release were investigated by analysis of platelet aggregation curves. ISDN, 2-ISMN and 5-ISMN (isosorbide nitrates, ISN) inhibited both ADP- and epinephrine (EPI)-induced platelet aggregation. ISN affected specifically the extent of ADP-induced aggregation and the velocity of EPI-induced effects. 2-ISMN was more potent against platelet aggregation compared to ISDN and 5-ISMN. The isosorbide nitrates were poor inhibitors of both arachidonic acid-induced aggregation and platelet TxB2 release. The differential inhibition by the three isosorbide nitrates of endogenous TxB2 release during ADP-induced aggregation further indicates that 2-ISMN is a significantly more potent platelet inhibitor than either ISDN or 5-ISMN. These studies suggest a role of the metabolites in modulating the pharmacological effects of ISDN on platelet activity.
Similar content being viewed by others
References
Hillis, L. D., Braunwald, E. (1978) N. Engl. J. Med. 299, 695–702.
Silver, M. D., Baroldi, G., Mariani, F. (1980) Circulation 61, 219–227.
Dalen, J. E., Ockene, J. S., Alpert, J. S. (1982) Am. Heart J. 104, 1113–1124.
Haerem, J. W. (1972) Atherosclerosis 15, 199–213.
El-Maraghin, Genton, E. (1980) Circulation 62, 936–944.
Distante, A., Maseri, A., Severi, S., Biagini, A., Chiercha, S. (1979) Am. J. Cardiol. 44, 533–540.
Krantz, J. C. (1982) “Organic Nitrates”. P. Needleman (Editor), Handbook of Experimental Pharmacology, Springer-Verlag, New York, 40, 5–7.
Glusa, E., Markwarsr, F. (1974) Haemostasis 3, 249–256.
Saxon, A., Kattlove, H. E. (1976) Blood 47, 957–961.
Schafer, A. I., Alexander, R. W., Handin, R. I. Jr. (1980) Blood 55, 649–654.
Rolland, P. H., Jouve, R., Pellegrin, E., Mercier, C., Serradimigni, A. (1984) Arteriosclerosis 4, 70–79.
Hampton, J. R., Harrison, M. J. G., Honour, A. J., Mitchell, J. R. A. (1961) Cardiovasc. Res. 1, 101–107.
Garratini, S. G. (1978) Raven Press, New York, 61–73.
Levin, R. I., Jaffe, E. A., Weksler, B. B., Tack-Goldman, K. (1982) J. Clin. Invest. 67, 762–769.
Rowan, R. M., Fraser, L., McDonald, G. A. (1979) Clin. Lab. Haemat. 1, 21–40.
Rolland, P. H., Martin, P. M., Jacquemier, J., Rolland, A. M., Toga, M. (1980) J. Natl. Cancer Instit. 64, 1061–1070.
Rolland, P. H., Bory, M., Leca, F., Sainsous, J., Gueydon, E., Juhan, I., Serradimigni, A., Cano, J. P. (1984) Prostagl. Leukotr. Med. 16, 333–346.
Jouve, R., Rolland, P. H., Delboy, C., Mercier, C. (1984) Am. Heart J. 102, 45–52.
Keith, R. A., Burkman, A. M., Sokoloski, T. D., Fertel, R. H. (1983) J. Pharmacol. Exp. Ther. 225, 29–34.
Galvas, P. E., Disalvo, J. (1983) J. Pharmacol. Exp. Ther. 224, 373–378.
Adelstein, R. S., Pollard, T. D. (1978) Prog. Hemostas. Thromb. 4, 37–58.
Hathaway, D. R., Adelstein, R. S. (1979) Proc. Natl. Acad. Sci. U.S.A. 76, 1653–1657.
Carroll, R. C., Guerrard, J. M. (1982) Blood 59, 466–471.
Verstraete, M. (1982) Haemostasis 12, 317–336.
Harfenist, E. J., Guccione, M. A., Packham, M. A., Kingough-Rathbone, R. L., Mustard, J. F. (1982) Blood 59, 956–962.
Peerschke, E. I. (1982) Blood 60, 71–77.
Bruyneel, K., Rosseel, M. T., Bogaert, M. G. (1982) Arzneim. Forsch. Drug Res. 32, 769–773.
Maddock, J., Lewis, P. A., Woodward, A., Massey, P. R., Kennedy, S. (1983) J. Chromatography 272, 129–136.
Abshagen, U., Sporl-Radun, S. (1981) Europ. J. Clinical Pharmacol. 19, 424–429.
Santoni, Y., Rolland, P. H., Cano, J. P. (1984) J. Chromatog. 306, 165–173.
Reed, D. E., Akester, J. M., Prather, J. F., Tuckdsh, J. R., Maccurdy, D. H., Yeh, C. (1977) J. Pharmacol. Exp. Ther. 202, 32–37.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Rolland, P.H., Sampol, J., Lacarelle, B. et al. Differential Inhibitory Effects of Isosorbide Dinitrate and its Mononitrate Metabolites on Platelet Aggregation and Thromboxane Formation. Pharm Res 2, 87–90 (1985). https://doi.org/10.1023/A:1016346913143
Issue Date:
DOI: https://doi.org/10.1023/A:1016346913143